B. Haines

发表

An Unbiased Oncology Compound Screen to Identify Novel Combination Strategies

Yair Benita, J. O'neil, I. Feldman, 2016, Molecular Cancer Therapeutics.

SAR profiles of spirocyclic nicotinamide derived selective HDAC1/HDAC2 inhibitors (SHI-1:2).

C. Kenific, Melissa Chenard, A. Kral, 2008, Bioorganic & medicinal chemistry letters.

Small Interfering RNA-Mediated Gene Silencing in T Lymphocytes1

Michael T. McManus, Phillip A Sharp, P. Sharp, 2002, The Journal of Immunology.

A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors

C. Paweletz, H. Dai, I. Feldman, 2010, BMC Medical Genomics.

Delayed and Prolonged Histone Hyperacetylation with a Selective HDAC1/HDAC2 Inhibitor.

C. Kenific, Melissa Chenard, A. Kral, 2014, ACS medicinal chemistry letters.

Exploring the pharmacokinetic properties of phosphorus-containing selective HDAC 1 and 2 inhibitors (SHI-1:2).

J. Grimm, Melissa Chenard, A. Kral, 2009, Bioorganic & medicinal chemistry letters.

Optimization of biaryl Selective HDAC1&2 Inhibitors (SHI-1:2).

Melissa Chenard, A. Kral, B. Haines, 2008, Bioorganic & medicinal chemistry letters.

Combination of the mTOR Inhibitor Ridaforolimus and the Anti-IGF1R Monoclonal Antibody Dalotuzumab: Preclinical Characterization and Phase I Clinical Trial

J. Baselga, J. Bendell, I. Braña, 2014, Clinical Cancer Research.

Germline diversity of the expressed BALB/c VhJ558 gene family.

B. Haines, C. Angeles, P. Mclean, 2001, Molecular immunology.

Germline structure and differential utilization of Igha and Ighb VH10 genes.

B. Haines, A. Pearlman, E. Whitcomb, 1999, Journal of immunology.

ONCR-177, an Oncolytic HSV-1 Designed to Potently Activate Systemic Antitumor Immunity

B. Haines, C. Quéva, L. Lerner, 2020, Cancer Immunology Research.

Identification of the transgenic integration site in 2C T cell receptor transgenic mice

B. Haines, A. Luch, C. Ryu, 2018, Transgenic Research.

Ridaforolimus (MK-8669) synergizes with Dalotuzumab (MK-0646) in hormone-sensitive breast cancer

B. Haines, S. Weroha, P. Haluska, 2016, BMC Cancer.

Accessibility changes across the mouse Igh‐V locus during B cell development

B. Haines, P. Brodeur, 1998, European journal of immunology.

Gene silencing using micro-RNA designed hairpins.

Michael T. McManus, P. Sharp, Jianzhu Chen, 2002, RNA.

Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma.

C. Moskaluk, J. Aster, B. Bernstein, 2014, Cancer discovery.

Triple-Negative Breast Cancer and Adenoid Cystic Carcinoma Discovery of Biomarkers Predictive of GSI Response in

C. Moskaluk, J. Aster, B. Bernstein, 2014 .

Gauging NOTCH1 Activation in Cancer Using Immunohistochemistry

G. Pinkus, J. Aster, L. Chirieac, 2013, PloS one.

Design of an Interferon-Resistant Oncolytic HSV-1 Incorporating Redundant Safety Modalities for Improved Tolerability

B. Haines, C. Quéva, J. Glorioso, 2020, Molecular therapy oncolytics.

Recombination Activating Genes (RAG) in Lymphoma Development

Jianzhu Chen, B. Haines, C. Ryu, 2006, Cell cycle.

Small Interfering RNA-Mediated Gene Silencing in T Lymphocytes

Michael T. McManus, P. Sharp, Jianzhu Chen, 2002 .

Block of T cell development in P53-deficient mice accelerates development of lymphomas with characteristic RAG-dependent cytogenetic alterations.

Maria F. Fragoso, A. Protopopov, R. DePinho, 2006, Cancer cell.

The T-Cell Receptor β Variable Gene Promoter Is Required for Efficient Vβ Rearrangement but Not Allelic Exclusion

Jianzhu Chen, B. Haines, C. Ryu, 2004, Molecular and Cellular Biology.

A quantitative volumetric micro-computed tomography method to analyze lung tumors in genetically engineered mouse models.

Raquel S. Sevilla, B. Haines, Christopher Tong, 2009, Neoplasia.

Evidence of mTOR Activation by an AKT-Independent Mechanism Provides Support for the Combined Treatment of PTEN-Deficient Prostate Tumors with mTOR and AKT Inhibitors.

C. Paweletz, P. Majumder, K. Kunii, 2012, Translational oncology.

The T cell receptor β enhancer promotes access and pairing of Dβ and Jβ gene segments during V(D)J recombination

Jianzhu Chen, B. Haines, C. Ryu, 2003, Proceedings of the National Academy of Sciences of the United States of America.

High Levels of Expression of P-glycoprotein/Multidrug Resistance Protein Result in Resistance to Vintafolide

E. Schmidt, J. O'neil, R. Cristescu, 2016, Molecular Cancer Therapeutics.

Development of intravenously administered synthetic RNA virus immunotherapy for the treatment of cancer

T. Ashburn, B. Haines, C. Quéva, 2021, Nature Communications.

Combination of EP4 antagonist MF-766 and anti-PD-1 promotes anti-tumor efficacy by modulating both lymphocytes and myeloid cells

Andrew M Haidle, Chunsheng Zhang, Yongxin Han, 2021, Oncoimmunology.

Identification of the transgenic integration site in 2C T cell receptor transgenic mice

B. Haines, A. Luch, C. Ryu, 2018, Transgenic Research.

The T-cell receptor beta variable gene promoter is required for efficient V beta rearrangement but not allelic exclusion.

Jianzhu Chen, B. Haines, C. Ryu, 2004, Molecular and cellular biology.

Combination of themTOR Inhibitor Ridaforolimus and the Anti-IGF1R Monoclonal Antibody Dalotuzumab: Preclinical Characterization and Phase I Clinical Trial

S. Cosimo, J. Bendell, B. Haines, 2014 .

Ridaforolimus (MK-8669) synergizes with Dalotuzumab (MK-0646) in hormone-sensitive breast cancer

B. Haines, S. Weroha, P. Haluska, 2016, BMC Cancer.

The T cell receptor beta enhancer promotes access and pairing of Dbeta and Jbeta gene segments during V(D)J recombination.

Jianzhu Chen, B. Haines, C. Ryu, 2003, Proceedings of the National Academy of Sciences of the United States of America.

Divergent kinetics differentiate the mechanism of action of two HDAC inhibitors.

A. Kral, B. Haines, Thomas A. Miller, 2014, Biochemistry.

References and Notes Materials and Methods Som Text Fig. S1 Table S1 References a Microrna in a Multiple- Turnover Rnai Enzyme Complex

M. A. Rector, D. Bartel, A. Caudy, 2022 .

Accessibility changes across the mouse Igh‐V locus during B cell development

B. Haines, P. Brodeur, 1998, European journal of immunology.

Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma.

C. Moskaluk, J. Aster, B. Bernstein, 2014, Cancer discovery.

articleA gene expression signature of RAS pathway dependence predicts response to PI 3 K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors

C. Paweletz, H. Dai, I. Feldman, 2010 .

T cell activation and anti-tumor efficacy of anti-LAG-3 antibodies is independent of LAG-3 – MHCII blocking capacity

H. Hirsch, R. de Waal Malefyt, B. Haines, 2015, Journal of Immunotherapy for Cancer.

articleA gene expression signature of RAS pathway dependence predicts response to PI 3 K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors

C. Paweletz, H. Dai, I. Feldman, 2010 .